Levilimab · Ilsira

Monoclonal antibody

Also known as BCD-089

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid arthritis (Ilsira, levilimab) (RU)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also approved (2)
RU
  • Rheumatoid arthritis (Ilsira, levilimab)gxpnews.net
  • Cytokine release syndrome in severe COVID-19 (Ilsira, levilimab)ct.biocad.ru
Product first approved 2021

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Phase 2 (1)
Rheumatoid Arthritis
NCT03455842 · Biocad
2018-02-01 – 2019-10-22 · Seropositive RA
What this study did
Phase 1 (1)
Other / comorbidity
NCT03103438 · Biocad
2016-11 – 2017-05 · Healthy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for COVID-19: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Levilimab (Ilsira): this drugPhase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Elasomeran (Spikevax)ApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
IbuzatrelvirPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
GSK4396687
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.